Hemato Oncology Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Hemato Oncology Testing Market was valued at USD 3.2 billion in 2023 and is projected to grow at a CAGR of 14.2% from 2024 to 2032. This growth is driven by the increasing prevalence of hematological cancers, including leukemia, lymphoma, and multiple myeloma, leading to a rise in demand for advanced diagnostic tests. The advancements in diagnostic technology, in line with greater awareness of hematologic cancers and the benefits of early detection, are significantly boosting the market. The growing focus on early screening and the development of more specialized testing solutions continue to propel the market forward.

Hemato oncology testing is dedicated to the detection, diagnosis, and monitoring of blood-related cancers. These tests identify genetic mutations, chromosomal abnormalities, and other biomarkers associated with hematologic malignancies, enhancing the ability to manage these diseases more effectively.

The overall hemato oncology testing industry is categorized based on Product and Service, Cancer Type, Technology, End-use, and Region.

The market is segmented into kits and reagents, instruments, and software and services. The instrument segment includes next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, cytogenetics, and immunohistochemistry. In 2023, the kits and reagents segment dominated with a revenue of USD 1.7 billion, driven by the increasing demand for personalized medicine and advancements in diagnostic testing. Continuous research and development in hematology diagnostics further stimulates market expansion, with regulatory approvals from bodies like the FDA and EMA supporting growth.

The market is categorized into leukemia, lymphoma, and other cancers. Lymphoma held a leading market share of 51.3% in 2023 due to the rising incidence of both Hodgkin's and non-Hodgkin's lymphoma. Improved screening programs and diagnostic techniques contribute to the segment's dominance.

Key end-users include hospitals and clinics, diagnostic laboratories, and other entities. Diagnostic laboratories are expected to grow at a CAGR of 14.5% from 2024 to 2032, driven by increased investments in healthcare infrastructure and collaboration with research institutions. These advancements are improving testing capabilities and fostering innovation.

North America held the largest share of the global market in 2023, with 45.6%, due to rising rates of hematological cancers and the swift adoption of advanced testing technologies. The U.S. market is set to grow at a CAGR of 14.1% from 2024 to 2032, supported by advancements in healthcare infrastructure, favorable reimbursement policies, and regulatory endorsements for novel testing methods.

Product Code: 10902

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360º synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in diagnosis rate of hematological cancers
  - 3.2.1.2 Improved healthcare infrastructure
  - 3.2.1.3 Advancement in diagnostic technologies
  - 3.2.1.4 Increasing incidence of hematologic malignancies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Competition from alternative diagnostic methods
  - 3.2.2.2 High maintenance and operational cost
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Instrument
- 5.2.1 Next-generation sequencing (NGS)
- 5.2.2 Polymerase chain reaction (PCR)
- 5.2.3 Flow cytometry
- 5.2.4 Cytogenetics
- 5.2.5 Immunohistochemistry (IHC)
- 5.2.6 Other technologies
5.3 Kits and reagents
5.4 Software and service

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Leukemia
- 6.2.1 Acute lymphoblastic leukemia (ALL)
- 6.2.2 Acute myeloid leukemia (AML)
- 6.2.3 Chronic lymphocytic leukemia (CLL)
- 6.2.4 Chronic myeloid leukemia (CML)
6.3 Lymphoma
- 6.3.1 Hodgkin lymphoma
- 6.3.2 Non-Hodgkin lymphoma (NHL)
6.4 Other cancer types

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Diagnostic laboratories
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 Abbott Laboratories
9.2 ARUP Laboratories
9.3 Bio-Rad Laboratories Inc.
9.4 Danaher Corporation (Integrated DNA Technologies, Inc.)
9.5 Entrogen Inc.
9.6 F. Hoffmann-La Roche Ltd
9.7 Illumina, Inc.
9.8 Invivoscribe, Inc.
9.9 Invitae Corporation (Archerdx, Inc.)
9.10 QIAGEN N.V.
9.11 Thermo Fisher Scientific, Inc.
9.12 Vela Diagnostics